Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Regeneron Pharmaceuticals Inc (REGN) vs Toyota Motor Corp (TM) Price & Performance

Regeneron Pharmaceuticals IncTrade
Toyota Motor CorpTrade

Price performance (Past 24H)

Key statistics

Regeneron Pharmaceuticals Inc vs Toyota Motor Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Toyota Motor Corp trades at $194.49 (market cap $228.43B). The key difference: Toyota Motor Corp is far larger — about 2.7× Regeneron Pharmaceuticals Inc's market cap, and Toyota Motor Corp pays the higher dividend (3.27%). Which is the better fit depends on your goals.

REGNTM
Market Cap
$83.43B$228.43B
Sector
HealthConsumer Cyclical
52-Week High
$852.03$248.29
52-Week Low
$555.51$166.50
Enterprise Value
$78.14B$427.29B
Dividend Yield
0.46%3.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

Toyota Motor Corp

Toyota Motor (TM) trades at $191.45, down 2.87% amid bearish technical signals, though fundamentals remain strong with attractive valuation metrics including a P/E of 8.51 and P/S of 0.74. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $7.57 exceeding estimates by 62%. Recent news highlights strong demand for hybrid models like the RAV4 and strategic partnerships, though tariff threats and a global recall present headwinds.

TM offers value with solid profitability and growth, but faces near-term technical pressure and geopolitical risks. The stock's undervaluation relative to DCF estimates around $342 presents opportunity, yet investors must weigh competitive pressures and macroeconomic uncertainties against the company's operational strength and market leadership in hybrid technology.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN

About Toyota Motor Corp

Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.

Read more on TM